Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
In Dec, 2019 Kamada signed a deal with Alvotech for commercialization of biosimilars in Israel while Techno Science also signed an agreement with Kishi Kasei for co-developing biosimilar aflibercept
Mylan and Biocon launched its Ogivri (trastuzumab-dkst) in…
Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics possessing similar therapeutic properties in terms of potency- safety- and efficacy to original biologic products. The companies are focusing…
In the last 20 years the global Biopharma space has changed a lot with ups and downs of companies and their growth. This analysis has found the multiple acquisitions and mergers along with the launch of several blockbusters leading to jump in growth and revenue of numerous companies. Pfizer acquired Warner-Lambert in 2000 to gain…

